Eli Lilly weight loss drug Zepbound approved by FDA

The Food and Drug Administration said it approved Zepbound injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes or high cholesterol, for use, in addition to a reduced calorie diet and increased physical activity. Tirzepatide, the active ingredient in Zepbound, is already approved under the trade name Mounjaro to be used along with diet and exercise to help improve blood sugar in adults with type 2 diabetes mellitus. The FDA said Zepbound’s effectiveness for chronic weight management in combination with a reduced-calorie diet and increased physical activity was established in two randomized, double-blind, placebo-controlled trials of adults with obesity or overweight with at least one weight-related condition. The FDA granted the approval to Eli Lilly.